Skip to main
ILMN

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 33%
Hold 27%
Sell 7%
Strong Sell 7%

Bulls say

Illumina is positioned for growth in the life science and clinical lab markets through its high-throughput sequencing technology and low throughput tools for smaller data output applications. The company has a strong track record of beating revenue and earnings expectations and raises guidance accordingly. As clinical adoption of their on-market tests expands, Illumina expects sustained revenue growth and is taking proactive measures to optimize their cost structure. While there are headwinds from China, tariffs, and the research market, Illumina's strong hold on the clinical sequencing market and potential growth opportunities in early detection and MRD make it a promising investment.

Bears say

Illumina is experiencing strong momentum in its instruments segment, partly driven by end-market demand in clinical customers and continued lab investment for future tests. Despite some discounting, the company did not update their expectations for quarterly X placements, and they expect more demand than supply for their instruments. Additionally, Illumina is focused on capturing longer-term business, rather than offering lower list prices in the near term. However, there are concerns over future policy changes which may pause any new projects in sequencing, and both the academic and pharma markets are showing limited growth potential for the company.

Illumina (ILMN) has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 33% recommend Buy, 27% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Buy based on their latest research and market trends.

According to 15 analysts, Illumina (ILMN) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $201.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $201.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.